Oncology Pharma Inc.
ONPH · OTC
3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $14 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $14 | $0 | $1 |
| Operating Income | -$0 | -$14 | -$0 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$105 | -$83 | $0 | -$0 |
| Pre-Tax Income | -$105 | -$97 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$105 | -$97 | -$0 | -$1 |
| % Margin | – | – | – | – |
| EPS | -3.42 | -6.76 | -0.12 | -0.72 |
| % Growth | 49.4% | -5,533.3% | 83.3% | – |
| EPS Diluted | -3.42 | -6.76 | -0.12 | -0.72 |
| Weighted Avg Shares Out | 31 | 14 | 2 | 1 |
| Weighted Avg Shares Out Dil | 31 | 14 | 2 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $105 | $83 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$15 | -$0 | -$1 |
| % Margin | – | – | – | – |